UCB says receives CHMP clearance for Neupro drug
BRUSSELS, April 25 (Reuters) - Belgian pharmaceutical group UCB (UCB.BR) said on Friday that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for its Neupro drug to treat restless legs syndrome (RLS).
"This is earlier than expected...this drug has a huge potential," a UCB spokeswoman said.









